

“Weighing In” on Antibiotic Dosing in Obese Patients

by Dana Siu, Pharm.D.

References

1. Devine BJ. Gentamicin Therapy. *Drug Intelligence & Clinical Pharmacy* 1974; 8(11):650-5.
2. Wurtz R, Itokazu G, Rodvold K. Antimicrobial dosing in obese patients. *Clin Infect Dis* 1997; 25 (1):112-8.
3. Cheymol G. Effects of obesity on pharmacokinetics implications for drug therapy. *Clin Pharmacokinet* 2000; 39 (3):215-31.
4. Bearden DT, Rodvold KA. Dosage adjustments for antibacterials in obese patients: applying clinical pharmacokinetics. *Clin Pharmacokinet* 2000; 38 (5):415-26.
5. NHLBI Obesity Education Initiative Expert Panel. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: The Evidence Report. NIH Publication No. 998-4083. National Institutes of Health. September 1998.
6. Bauer LA. Applied clinical pharmacokinetics / by Larry A. Bauer. New York :: McGraw-Hill Medical Pub. Division; 2001. 759 pp.
7. Blouin RA, Kolpek JH, Mann HJ. Influence of obesity on drug disposition. *Clin Pharm* 1987; 6 (9):706-14.
8. Winter ME. Basic clinical pharmacokinetics / Michael E. Winter. 4th ed. ed. Philadelphia :: Lippincott Williams & Wilkins; 2004.
9. Blouin RA, Mann HJ, Griffen WO, Jr. et al. Tobramycin pharmacokinetics in morbidly obese patients. *Clin Pharmacol Ther* 1979; 26 (4):508-12.
10. Bauer LA, Blouin RA, Griffen WO, Jr. et al. Amikacin pharmacokinetics in morbidly obese patients. *Am J Hosp Pharm* 1980; 37 (4):519-22.
11. Bauer LA, Edwards WA, Dellinger EP et al. Influence of weight on aminoglycoside pharmacokinetics in normal weight and morbidly obese patients. *Eur J Clin Pharmacol* 1983; 24 (5):643-7.
12. Leader WG, Tsubaki T, Chandler MH. Creatinine-clearance estimates for predicting gentamicin pharmacokinetic values in obese patients. *Am J Hosp Pharm* 1994; 51 (17):2125-30.
13. Traynor AM, Nafziger AN, Bertino JS, Jr. Aminoglycoside dosing weight correction factors for patients of various body sizes. *Antimicrob Agents Chemother* 1995; 39 (2):545-8.
14. Allard S, Kinzig M, Boivin G et al. Intravenous ciprofloxacin disposition in obesity. *Clin Pharmacol Ther* 1993; 54 (4):368-73.
15. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. *Nephron* 1976; 16 (1):31-41.
16. Dionne RE, Bauer LA, Gibson GA et al. Estimating creatinine clearance in morbidity obese patients. *Am J Hosp Pharm* 1981; 38 (6):841-4.
17. Erstad BL. Which weight for weight-based dosage regimens in obese patients? *Am J Health Syst Pharm* 2002; 59 (21):2105-10.
18. Salazar DE, Corcoran GB. Predicting creatinine clearance and renal drug clearance in obese patients from estimated fat-free body mass. *Am J Med* 1988; 84 (6):1053-60.
19. Blouin RA, Brouwer KL, Record KE et al. Amikacin pharmacokinetics in morbidly

(Continued on page 2)

A University of Washington Drug Information Center publication
Distributed monthly by authority of the Pharmacy and Therapeutics Committee
Editor: Nelda A. Murri, Pharm.D. (206) 598-6612 – Asst. Editor: Elizabeth Rudy, D.V.M., R.Ph.
Department of Pharmacy Services / School of Pharmacy

Copyright © 2006 by the University of Washington
Also published on the World Wide Web at <http://uw.prnrx.org/therapyTopics.asp>
No material may be reproduced in whole or in part without written permission from the editor.

- obese patients undergoing gastric-bypass surgery. *Clin Pharm* 1985; 4 (1):70-2.
20. Kampmann JP, Klein H, Lumholtz B et al. Ampicillin and propylthiouracil pharmacokinetics in intestinal bypass patients followed up to a year after operation. *Clin Pharmacokinet* 1984; 9 (2):168-76.
 21. Yuk J, Nightingale CH, Sweeney K et al. Pharmacokinetics of nafcillin in obesity. *J Infect Dis* 1988; 157 (5):1088-9.
 22. Miskowiak J, Andersen B, Nielsen VG. Absorption of oral penicillin before and after gastroplasty for morbid obesity. *Pharmacology* 1985; 31 (2):115-20.
 23. Forse RA, Karam B, MacLean LD et al. Antibiotic prophylaxis for surgery in morbidly obese patients. *Surgery* 1989; 106 (4):750-6; discussion 6-7.
 24. Pories WJ, van Rij AM, Burlingham BT et al. Prophylactic cefazolin in gastric bypass surgery. *Surgery* 1981; 90 (2):426-32.
 25. Yost RL, Derendorf H. Disposition of cefotaxime and its desacetyl metabolite in morbidly obese male and female subjects. *Ther Drug Monit* 1986; 8 (2):189-94.
 26. McGregor JA, Gordon SF, Krotec J et al. Results of a randomized, multicenter, comparative trial of a single dose of cefotetan versus multiple doses of cefoxitin as prophylaxis in cesarean section. *Am J Obstet Gynecol* 1988; 158 (3 Pt 2):701-6.
 27. Chen M, Nafziger AN, Bertino JS. Pharmacodynamic (PD) Target Attainment (TA) in Normal Size (N), Obese (OB) and Morbidly Obese (MOB) Healthy Volunteers (HV) Receiving One Gram Doses of Ertapenem (ETP). In: American Society for Clinical Pharmacology and Therapeutics. Orlando, Florida; 2005.
 28. Bertino JS, Michalak C, Victory A, et al. Comparative Pharmacokinetics of Ertapenem in Normal Weight Obese and Morbidly Obese Adults. In: 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, D.C.; 2004.
 29. Bearden DT, Earle SB, McConnell DB et al. Pharmacokinetics of Meropenem in Extreme Obesity. Poster presented at the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2005 Dec; Washington, DC.
 30. Caldwell JB, Nilsen AK. Intravenous ciprofloxacin dosing in a morbidly obese patient. *Ann Pharmacother* 1994; 28 (6):806.
 31. Prince RA, Pincheira JC, Mason EE et al. Influence of bariatric surgery on erythromycin absorption. *J Clin Pharmacol* 1984; 24 (11-12):523-7.
 32. Davis RL, Quenzer RW, Weller S, et al. Acyclovir pharmacokinetics in morbid obesity. In: Programs and abstracts of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, D.C.; 1991.
 33. Vadieli K, Lopez-Berestein G, Luke DR. Disposition and toxicity of amphotericin-B in the hyperlipidemic Zucker rat model. *Int J Obes* 1990; 14 (6):465-72.
 34. Erstad BL. Dosing of medications in morbidly obese patients in the intensive care unit setting. *Intensive Care Med* 2004; 30 (1):18-32.
 35. Dvorchik BH, Damphousse D. The pharmacokinetics of daptomycin in moderately obese, morbidly obese, and matched nonobese subjects. *J Clin Pharmacol* 2005; 45 (1):48-56.
 36. Cohen LG, DiBiasio A, Lisco SJ et al. Fluconazole serum concentrations and pharmacokinetics in an obese patient. *Pharmacotherapy* 1997; 17 (5):1023-6.
 37. Stein GE, Schooley SL, Peloquin CA et al. Pharmacokinetics and pharmacodynamics of linezolid in obese patients with cellulitis. *Ann Pharmacother* 2005; 39 (3):427-32.
 38. Bauer LA, Black DJ, Lill JS. Vancomycin dosing in morbidly obese patients. *Eur J Clin Pharmacol* 1998; 54 (8):621-5.
 39. Blouin RA, Bauer LA, Miller DD et al. Vancomycin pharmacokinetics in normal and morbidly obese subjects. *Antimicrob Agents Chemother* 1982; 21 (4):575-80.
 40. Vance-Bryan K, Guay DR, Gilliland SS et al. Effect of obesity on vancomycin pharmacokinetic parameters as determined by using a Bayesian forecasting technique. *Antimicrob Agents Chemother* 1993; 37 (3):436-40.